Categories: Big DataNews

dQ&A Announces Beta Release of New AI Insights Platform – Instant, Reliable Insights for the Diabetes Market

Breakthrough natural-language platform delivers trustworthy, data-driven answers in seconds.

SAN FRANCISCO, Oct. 17, 2025 /PRNewswire/ — dQ&A, the leader in diabetes market research, today announced the beta release of its new AI-powered diabetes insights platform: a natural-language decision tool that quickly answers a wide range of diabetes business questions, using dQ&A’s expansive database of primary research.

“Working with AI experts, we’re creating a ‘killer app’ for diabetes research,” said Richard Wood, CEO of dQ&A. “Our new solution should dramatically reduce decision-making time for business leaders – unlocking the insights of big data, without any of the friction. Suddenly, the answers are at your fingertips.”

Opening Up Insights

The new platform allows users to ask complex business and research questions in plain English. It interprets a user’s question, identifies and analyzes the relevant data points, and quickly creates visualizations ready to drop into reports or presentations.

dQ&A achieves this by querying its proprietary ‘data lake’ of diabetes knowledge – containing millions of responses from tens of thousands of patients and prescribers, across dozens of products, in nine countries, compiled over 15 years. The data is longitudinal, representative and reliable, and forms the basis for dQ&A’s successful range of diabetes Data Services products.

Built thoughtfully, the new AI-based platform accesses this knowledge, eliminating the steps of data analysis and presentation, and opening up insights for all.

Timeframe for Availability

“I’m so excited to launch our beta program,” said Christianne Pang, VP of Product at dQ&A. “We’ve been working hard behind the scenes to deliver a robust, intuitive solution. Now it’s time for real-world testing — and we expect the productivity gains to be immediately noticeable.”

dQ&A will invite selected Data Services clients to participate in the beta program over the coming weeks, ahead of broader availability. The new platform is expected to launch formally in early 2026.

Organizations interested in requesting a demonstration or joining the beta program are encouraged to contact dQ&A directly.

About dQ&A

dQ&A is the Real Deal for diabetes market research. For those who drive critical diabetes research decisions in their organization, dQ&A is your partner for insights and expertise. With decades of diabetes experience in classic and cutting-edge methodologies, coupled with a deep understanding of the research nuances unique to diabetes, we know what it takes to get the right answers. dQ&A’s exclusive panels in the United States, Canada and Europe generate authentic, candid responses from hard-to-find participants. This work is our focus and passion. Many of our lives have been directly impacted by diabetes. Partner with a caring and passionate team that truly gets your business, products, prescribers, and your end customer.

For more information, please contact dQ&A at info2@d-qa.com or visit us on the web at
d-qa.com.

Media Contact:
Amy Funk

917-437-8590

View original content:https://www.prnewswire.com/news-releases/dqa-announces-beta-release-of-new-ai-insights-platform—instant-reliable-insights-for-the-diabetes-market-302587971.html

SOURCE dQ&A Market Research

Staff

Recent Posts

From Follower to Force: China’s Biotech Sector Enters the Global Clinical Mainstream

WASHINGTON, Dec. 26, 2025 /PRNewswire/ -- Over the past decade, China has evolved from a biotechnology…

3 hours ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…

6 hours ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…

6 hours ago

Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources

DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…

6 hours ago

A Christmas Message to the DEA’s Diversion Anti Marijuana Cabal

This Christmas season, President Trump's executive action to advance rescheduling and medical research has finally…

9 hours ago

Kanazawa University research: High-speed AFM imaging reveals how brain enzyme forms dodecameric ring structure

KANAZAWA, Japan, Dec. 26, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa…

15 hours ago